A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Unless otherwise stated in this Annual Report or the context otherwise requires, references to: •“GeneDx Holdings” refer to GeneDx Holdings Corp., a Delaware corporation; •“Legacy GeneDx” refer to GeneDx, LLC, a Delaware limited liability company, which we acquired on April 29, 2022 (the “Acquisition”); •“Legacy Sema4” refer to Sema4 OpCo Inc., a Delaware corporation, which consummated the business combination with CM Life Sciences, Inc. (“CMLS”) on July 22, 2021 (the “Business Combination”); •“Fabric Genomics” refer to Fabric Genomics, Inc., a Delaware corporation, which we acquired on May 5, 2025 (the “Merger”); and •“we,” “us” and “our,” the “Company” and “GeneDx” refer, as the context requires, to GeneDx Holdings and its consolidated subsidiaries. The Company’s Class A common stock and public warrants are listed on the Nasdaq Global Select Market under the symbols “WGS” and “WGSWW,” respectively.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 428M | 428M | 305M | 203M | - | 212M |
| Net Income | -21M | -21M | -52M | -176M | -549M | -245M |
| EPS | $-0.73 | $-0.73 | $-1.94 | $-7.23 | $-1,769.79 | $-74.91 |
| Free Cash Flow | 14M | 14M | -34M | -185M | -326M | -200M |
| ROIC | -4.0% | -6.4% | -17.6% | -62.6% | -374.7% | -61.5% |
| Gross Margin | 69.7% | 69.7% | 63.6% | 44.4% | - | -7.8% |
| Debt/Equity | 0.17 | 0.17 | 0.22 | 0.23 | 0.04 | 0.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -13M | -13M | -23M | -181M | -668M | -446M |
| Operating Margin | -3.1% | -3.1% | -7.6% | -89.2% | - | -210.3% |
| ROE | -6.8% | -7.6% | -21.3% | -77.1% | -216.4% | -63.2% |
| Shares Outstanding | 29M | 29M | 27M | 24M | 1M | 24M |
| Metric | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 179M | 212M | N/A | 203M | 305M | 428M | 428M |
| Gross Margin | 2.2% | -7.8% | N/A | 44.4% | 63.6% | 69.7% | 69.7% |
| R&D | 73M | 105M | 86M | 58M | 46M | 72M | 72M |
| SG&A | 101M | 206M | 216M | 134M | 105M | 151M | 151M |
| EBIT | -242M | -446M | -668M | -181M | -23M | -13M | -13M |
| Op. Margin | -134.9% | -210.3% | N/A | -89.2% | -7.6% | -3.1% | -3.1% |
| Net Income | N/A | -245M | -549M | -176M | -52M | -21M | -21M |
| Net Margin | N/A | -115.6% | N/A | -86.8% | -17.1% | -4.9% | -4.9% |
| Non-Recurring | 0 | 0 | 234M | 17M | 1.8M | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | N/A | -61.5% | N/M | -62.6% | -17.6% | -6.4% | -4.0% |
| ROE | N/A | -63.2% | -216.4% | -77.1% | -21.3% | -7.6% | -6.8% |
| ROA | N/A | -44.3% | -111.8% | -42.0% | -12.5% | -4.5% | -4.0% |
| Cash Flow | |||||||
| Op. Cash Flow | -93M | -190M | -319M | -180M | -28M | 33M | 33M |
| Free Cash Flow | -117M | -200M | -326M | -185M | -34M | 14M | 14M |
| Owner Earnings | -225M | -432M | -420M | -214M | -60M | -24M | -24M |
| CapEx | 24M | 9.4M | 7.2M | 5.3M | 5.5M | 19M | 19M |
| Maint. CapEx | 12M | 22M | 59M | 34M | 22M | 25M | 25M |
| Growth CapEx | 12M | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 12M | 22M | 59M | 34M | 22M | 25M | 25M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 57.1% | 57.1% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 230M | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 120M | 219M | 42M | 326K | 9.1M | 32M | 32M |
| Debt Repayment | 0 | 537K | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -194M | -790M | -113M | -77M | -88M | -119M | -52M |
| Cash & Equiv. | 108M | 401M | 124M | 100M | 85M | 105M | 105M |
| Long-Term Debt | 19M | 11M | 6.3M | 53M | 52M | 48M | 48M |
| Debt/Equity | -0.07 | 0.03 | 0.04 | 0.23 | 0.22 | 0.17 | 0.17 |
| Interest Coverage | -97.8 | -157.4 | -208.2 | -162.1 | -7.7 | -5.2 | -5.2 |
| Equity | -330M | 388M | 254M | 228M | 245M | 308M | 308M |
| Total Assets | 252M | 554M | 491M | 419M | 419M | 524M | 524M |
| Total Liabilities | 582M | 166M | 237M | 191M | 174M | 216M | 216M |
| Intangibles | N/A | 0 | 187M | 173M | 159M | 168M | 168M |
| Retained Earnings | -330M | -575M | -1.1B | -1.3B | -1.4B | -1.4B | -1.4B |
| Working Capital | 101M | 382M | 68M | 124M | 143M | 159M | 159M |
| Current Assets | 174M | 484M | 213M | 182M | 198M | 268M | 268M |
| Current Liabilities | 73M | 101M | 144M | 59M | 55M | 109M | 109M |
| Per Share Data | |||||||
| EPS | -1,552,188.00 | -74.91 | -1,769.79 | -7.23 | -1.94 | -0.73 | -0.73 |
| Owner EPS | -30.32 | -17.85 | -532.54 | -8.81 | -2.21 | -0.84 | -0.84 |
| Book Value | -44.46 | 16.04 | 321.35 | 9.38 | 9.10 | 10.70 | 10.70 |
| Cash Flow/Share | -12.55 | -7.87 | -404.25 | -7.41 | -1.06 | 1.16 | 0.15 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 7.4M | 24.2M | 0.8M | 24.3M | 27.0M | 28.8M | 28.8M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -91.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | 270.1 | 135.0 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 9.2 | 0.8 | 0.3 | 8.6 | 12.5 | 6.2 |
| Price/Sales | 14.2 | 43.3 | N/A | 0.9 | 2.8 | 6.9 | 4.5 |
| FCF Yield | -4.2% | -5.6% | -169.4% | -276.3% | -1.6% | 0.4% | 0.7% |
| Market Cap | 2.8B | 3.6B | 193M | 67M | 2.1B | 3.9B | 1.9B |
| Avg. Price | 342.51 | 379.72 | 63.21 | 7.26 | 32.04 | 102.79 | 66.86 |
| Year-End Price | 375.87 | 148.17 | 7.39 | 2.76 | 78.05 | 133.79 | 66.86 |
GeneDx Holdings Corp. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 42.5%.
GeneDx Holdings Corp. (WGS) has a 5-year average return on invested capital (ROIC) of -37.0%. This is below average and may indicate limited pricing power.
GeneDx Holdings Corp. (WGS) has a market capitalization of $1.9B. It is classified as a small-cap stock.
GeneDx Holdings Corp. (WGS) does not currently pay a regular dividend.
GeneDx Holdings Corp. (WGS) operates in the Services-Health Services industry, within the Healthcare sector.
GeneDx Holdings Corp. (WGS) reported annual revenue of $428 million in its most recent fiscal year, based on SEC EDGAR filings.
GeneDx Holdings Corp. (WGS) has a net profit margin of -4.9%. The company is currently unprofitable.
GeneDx Holdings Corp. (WGS) generated $14 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
GeneDx Holdings Corp. (WGS) has a debt-to-equity ratio of 0.17. This indicates a conservatively financed balance sheet.
GeneDx Holdings Corp. (WGS) reported earnings per share (EPS) of $-0.73 in its most recent fiscal year.
GeneDx Holdings Corp. (WGS) has a return on equity (ROE) of -7.6%. A negative ROE may indicate losses or negative equity.
GeneDx Holdings Corp. (WGS) has a 5-year average gross margin of 42.5%. This indicates decent pricing power.
The Ledger Terminal provides 6 years of financial data for GeneDx Holdings Corp. (WGS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
GeneDx Holdings Corp. (WGS) has a book value per share of $10.70, based on its most recent annual SEC filing.